Evidence map›Paper›PMID 36334195›Full record

SynthesisCerebellum (London, England)2023

A Systematic Review on Anti-Yo/PCA-1 Antibody: Beyond Cerebellar Ataxia in Middle-Aged Women with Gynecologic Cancer.

Natalia Trombini Mendes, Nathalia Rossoni Ronchi, Guilherme Diogo Silva

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Cerebellum (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Natalia Trombini MendesNeuroimmunology Group, Department of Neurology, University of São Paulo, Avenida Dr Enéas de Carvalho Aguiar, CEP 05403-000, São Paulo, 255, Brazil. natalia.tmendes@gmail.com.
Nathalia Rossoni RonchiNeuroimmunology Group, Department of Neurology, University of Ribeirão Preto, São Paulo, Brazil.
Guilherme Diogo SilvaNeuroimmunology Group, Department of Neurology, University of São Paulo, Avenida Dr Enéas de Carvalho Aguiar, CEP 05403-000, São Paulo, 255, Brazil.
Universidade de São Paulo · BRUniversidade de Ribeirão Preto · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current understanding of anti-Yo/PCA1 antibody-associated cerebellar ataxia is based on case reports and small case series. Our goal was to summarize clinical features, highlighting atypical presentations and gaps of knowledge. Following the PRISMA guidelines, we systematically screened Pubmed/MEDLINE, Embase, Scopus, and Web of Science from inception to April 2022 for all case reports and series concerning anti-Yo antibody-associated cerebellar ataxia. We collected data on clinical presentation, investigation findings, and treatment outcomes. Of 379 included patients, 96% were female with gynecologic cancer (82%). Among men, 87% had an associated tumor, mainly of gastrointestinal origin. The median age was 60 years old. Pancerebellar ataxia was the main clinical feature, but extracerebellar findings were frequent during the disease course. Vertigo and imbalance can be present early in the disease course in about two thirds of patients, as a prodromal phase. Although neuroimaging usually is normal or shows cerebellar atrophy, inflammatory changes may also be present. More than half of the patients reported some improvement after immunotherapy. However, despite treatment, 84% of survivors were unable to walk unassisted on follow-up. Our study provides objective data and advances in current knowledge of anti-Yo antibody-associated cerebellar ataxia such as the description of prodromal symptoms, extracerebellar findings, and its presentations in males.

Indexed as

Cerebellar AtaxiaCerebellar DiseasesNeoplasmsParaneoplastic Cerebellar DegenerationAutoantibodiesDisease ProgressionFemaleHumansMaleMiddle AgedPurkinje CellsAutoantibodiesAnti-Yo AutoantibodiesCDR2 ProteinCerebellar AtaxiaParaneoplastic Cerebellar DegenerationPurkinje Cells

Identifiers

PMID36334195
OpenAlexW4308220670

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.